Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Waleed Ghanima

Showing results (181-190 of 205) with videos related to

Pageof 21
Sort By:
Journal of Thrombosis and Haemostasis : JTH|July 21, 2022
"Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients - 30 months follow-up": ReplyTrine-Lise Larsen, Herish Garresori, Jorunn Brekke, et al.
Journal of Thrombosis and Haemostasis : JTH|February 3, 2022
Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients - 30 months follow-upTrine-Lise Larsen, Herish Garresori, Jorunn Brekke, et al.
Blood Advances|August 5, 2025
Safety and Efficacy of Daratumumab in Immune ThrombocytopeniaGalina Tsykunova, Pål Andre Holme, Hoa Thi Thyuet Tran, et al.
Thrombosis Research|June 16, 2023
Arterial events in cancer patients treated with apixaban for venous thrombosisTrine-Lise Larsen, Marte Svalastoga, Jorunn Brekke, et al.
American Journal of Hematology|April 6, 2026
Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Adults With Primary Immune Thrombocytopenia (ADVANCE SC): A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 TrialNichola Cooper, Catherine M Broome, Yoshitaka Miyakawa, et al.
Research and Practice in Thrombosis and Haemostasis|November 30, 2022
SARS-CoV-2 vaccines are not associated with hypercoagulability in apparently healthy peopleLamya Garabet, Anna Eriksson, Eirik Tjønnfjord, et al.
Hematology (Amsterdam, Netherlands)|September 18, 2025
Iraqi consensus recommendations for the diagnosis and management of immune thrombocytopeniaAhmed Mjali, Bassam Francis Matti, Waleed Ghanima, et al.
Haematologica|June 26, 2025
Use of second-line and beyond maintenance therapies in adult patients with primary immune thrombocytopenia in Europe: a parallel study of six prospective multicenter national registriesGuillaume Moulis, Frederick Chen, Giuseppe Carli, et al.
Thrombosis Research|August 22, 2021
Efficacy and safety of a 12-week outpatient pulmonary rehabilitation program in Post-PE SyndromeGudula J A M Boon, Steffi M J Janssen, Stefano Barco, et al.
Blood Advances|November 27, 2019
Updated international consensus report on the investigation and management of primary immune thrombocytopeniaDrew Provan, Donald M Arnold, James B Bussel, et al.
Pageof 21

Showing results (181-190 of 205) with videos related to

Sort By:
Pageof 21
Journal of Thrombosis and Haemostasis : JTH|July 21, 2022
"Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients - 30 months follow-up": ReplyTrine-Lise Larsen, Herish Garresori, Jorunn Brekke, et al.
Journal of Thrombosis and Haemostasis : JTH|February 3, 2022
Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients - 30 months follow-upTrine-Lise Larsen, Herish Garresori, Jorunn Brekke, et al.
Blood Advances|August 5, 2025
Safety and Efficacy of Daratumumab in Immune ThrombocytopeniaGalina Tsykunova, Pål Andre Holme, Hoa Thi Thyuet Tran, et al.
Thrombosis Research|June 16, 2023
Arterial events in cancer patients treated with apixaban for venous thrombosisTrine-Lise Larsen, Marte Svalastoga, Jorunn Brekke, et al.
American Journal of Hematology|April 6, 2026
Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Adults With Primary Immune Thrombocytopenia (ADVANCE SC): A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 TrialNichola Cooper, Catherine M Broome, Yoshitaka Miyakawa, et al.
Research and Practice in Thrombosis and Haemostasis|November 30, 2022
SARS-CoV-2 vaccines are not associated with hypercoagulability in apparently healthy peopleLamya Garabet, Anna Eriksson, Eirik Tjønnfjord, et al.
Hematology (Amsterdam, Netherlands)|September 18, 2025
Iraqi consensus recommendations for the diagnosis and management of immune thrombocytopeniaAhmed Mjali, Bassam Francis Matti, Waleed Ghanima, et al.
Haematologica|June 26, 2025
Use of second-line and beyond maintenance therapies in adult patients with primary immune thrombocytopenia in Europe: a parallel study of six prospective multicenter national registriesGuillaume Moulis, Frederick Chen, Giuseppe Carli, et al.
Thrombosis Research|August 22, 2021
Efficacy and safety of a 12-week outpatient pulmonary rehabilitation program in Post-PE SyndromeGudula J A M Boon, Steffi M J Janssen, Stefano Barco, et al.
Blood Advances|November 27, 2019
Updated international consensus report on the investigation and management of primary immune thrombocytopeniaDrew Provan, Donald M Arnold, James B Bussel, et al.
Pageof 21